Skip to content
Menu

B. Riley Securities Reiterates Buy on Anika Therapeutics, Lowers Price Target to $17

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Madison El-Saadi reiterates Anika Therapeutics (NASDAQ:ANIK) with a Buy and lowers the price target from $23 to $17.

B. Riley Securities analyst Madison El-Saadi reiterates Anika Therapeutics (NASDAQ:ANIK) with a Buy and lowers the price target from $23 to $17.

Read at benzinga.com